Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
It promises fewer injections for vision loss patients
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
Subscribe To Our Newsletter & Stay Updated
